Skip to content

Clinical trials

Completed Glucose Intolerance trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glucose Intolerance Status: Completed Clear all

490 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20015
20026
20038
200413
200512
200617
200720
200823
200924
201015
201127
201221
201319
201427
201520
201629
201728
201838
201925
202016
202127
202226
202310
202415
202510
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed490

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Maastricht University Medical Center15
University of California, Los Angeles7
Mayo Clinic6
Singapore Institute of Food and Biotechnology Innovation6
Stanford University6
Yale University6
Clinical Nutrition Research Center, Illinois Institute of Technology5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)5
The University of Texas Health Science Center at San Antonio5
University of Michigan5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glucose Intolerance490
Obesity106
Diabetes Mellitus, Type 298
Insulin Resistance98
Diabetes Mellitus90
Prediabetic State56
Metabolic Syndrome46
Overweight34
Hypertension23
Hyperglycemia21

Trials

Showing 26 to 50 of 490. Each trial links to its page on Pharma Observatory.

390 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.